BERKELEY HEIGHTS, NJ - November 24, 2003
-Genta Incorporated (Nasdaq: GNTA) today announced that Genasense
TM
(oblimersen sodium), the Company's lead anticancer compound, will
be featured in a number of presentations at the annual meeting of
the American Society of Hematology in San Diego, CA from December
6-9, 2003. Investigators will discuss Genasense study results in a
variety of hematological cancers, such as non-Hodgkin's lymphoma,
multiple myeloma, and acute myeloid leukemia. Highlighted
presentations include the following:
- Friday, December 5, 2003; 7:00-10:00 a.m.
Clinical Aspects of Bcl-2 Antisense and Other Apoptosis-Based
Therapies
Meeting Chair: Dr. Larry Piro; Speakers: Dr. John Reed; Dr. Asher
Chanan-Khan; Dr.
Richard Klasa; Dr. Benjamin Koziner; Dr. Christopher
Chitambar
- Saturday, December 6, 2003; 6:00 p.m., Abstract # 1398
Clinical Activity of Genasense
TM
(oblimersen sodium), a Pro-Apoptotic to Bcl-2
Oligonucleotide, in Combination with Daunorubicin and Cytarabine:
A Phase I Study
in Previously Untreated Elderly Acute Myeloid Leukemia (AML)
Dr. Guido Marcucci, The Comprehensive Cancer Center, Ohio State
University
- Saturday, December 6, 2003; 6:00 p.m., Abstract # 1491
Genasense (Bcl-2 Antisense) Plus Rituximab is Active in
Patients with Relapsed or
Refractory B-Cell Non-Hodgkin's Lymphoma
Dr. Barbara Pro, The University of Texas M.D. Anderson Cancer
Center
- Sunday, December 7, 2003; 5:45 p.m., Abstract # 2533
Phase I/II Trial of Oblimersen Sodium, Dexamethasone and
Thalidomide in Patients
with Relapsed Multiple Myeloma
Dr. Ashrof Badros, Greenebaum Cancer Center, University of
Maryland
- Monday, December 8, 2003; 1:30 p.m., Abstract # 490
Genasense
TM
is Active and Well-Tolerated Both Alone and with R-CHOP in Mantle
Cell
Lymphoma (MCL)
Dr. John P. Leonard, Center of Lymphoma and Myeloma, Weill
Medical College of
Cornell University
- Monday, December 8, 2003; 3:30 p.m., Abstract # 628
Oblimersen (Bcl-2 Antisense) Enhances Antitumor Activity of
Bortezomib in Multiple
Myeloma and Non-Hodgkin's Lymphoma (NHL) Preclinical Models
Dr. Owen O'Connor, Memorial Sloan Kettering Cancer Center
About Genasense
Genasense is being broadly tested in more than 20 randomized and
non-randomized trials for its ability to increase the effectiveness
of current types of anticancer therapy for a number of diseases,
including acute and chronic leukemias, multiple myeloma,
non-Hodgkin's lymphoma, and cancers of the breast, colon, kidney,
lung, liver, pancreas, and prostate. Genasense is currently the
subject of a "rolling" New Drug Application (NDA) submission to the
Food and Drug Administration for the treatment of malignant
melanoma, based on positive data in the largest randomized trial
ever conducted for the treatment of advanced metastatic melanoma.
Genta has also completed enrollment in two additional randomized
trials (multiple myeloma and chronic lymphocytic leukemia) with
Genasense. Assuming positive data from one or more of these trials,
the Company intends to submit additional, supplemental New Drug
Applications (sNDAs) in a sequential manner after completion of its
application for melanoma.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense
TM
(oblimersen sodium), the Company's lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing. The
leading drug in Genta's small molecule program is Ganite
TM
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more information
about Genta, please visit our website at:
http://www.genta.com/
.
This press release contains forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks
and uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
